RALEIGH, NC, USA, May 2, 2023/EINPresswire.com/ -- Collaborations Pharmaceuticals, Inc. (CPI) with collaborators at the Research Center of Biotechnology RAS, Moscow ...
The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...
A team of scientists at the Salk Institute and Rutgers University has determined the molecular structure of HIV Pol, a protein that plays a key role in the late stages of HIV replication, the process ...
In a discovery that could spur the development of new therapies for more than 40 million HIV patients worldwide, scientists from Rutgers University and the Salk Institute determined the molecular ...
In a discovery that could spur the development of new therapies for more than 40 million HIV patients worldwide, scientists from Rutgers University and the Salk Institute determined the molecular ...
LA JOLLA—(July 6, 2022) Understanding how HIV replicates within cells is key for developing new therapies that could help nearly 40 million people living with HIV globally. Now, a team of scientists ...
Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.
The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...
The development of new classes of antiretroviral drugs, such as integrase inhibitors and CCR5-antagonistic entry inhibitors, has opened the possibility of considering regimens without NRTIs (Table 1).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback